Ann: Neuren appoints Bruce Hancox to board of dir, page-4

re: Ann: Neuren appoints Bruce Hancox to boar... Hmmmm i'd say to early for NEU to look on moving NNZ-2566 out if objective is to achieve maximum value & with only limited expenditure for it to get to the highest value point then fair to assume that it is not the objective here well yet anyway...

However

Perseis antibodies are now well overdue for the release of in-vivo study results & to add a couple of refreshers from previous releases.


"Perseis and Neuren are engaged in discussions with a number of global pharmaceutical companies and intend to enter into a licensing or collaborative agreement based on results from the confirmatory in vivo studies."


"Monoclonal antibodies are the leading approach to molecular targeting, the fastest growing segment of biopharmaceuticals. Molecularly targeted drugs and biologics exhibit highly specific activity, often with better efficacy and fewer side effects than traditional drugs. In 2008, the global monoclonal antibody market was valued at $27.4B with an annual growth rate of 30.8%. By 2016, six of the top ten billion dollar drugs are predicted to be monoclonal antibodies."



Interesting times ahead :-)